grant
Antibody signatures of HIV treatment effectiveness: toward low-cost rapid tests for treatment monitoring
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2031
NIHUS FederalResearch GrantFY2026AIDS VirusAIDS careAIDS testAIDS/HIV testAb responseAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAfrica South of the SaharaAllelism TestAntibodiesAntibody AvidityAntibody FormationAntibody ProductionAntibody TherapyAntibody titer measurementAreaAssayBindingBioassayBiological AssayCharacteristicsClientClinic VisitsClinicalComplementComplement ProteinsComplementation TestCost SavingsCosts and BenefitsCountryD-GlucoseDataData SetDextroseDiagnosisDiagnosticDisease ProgressionDrugsElectricityEpidemicFutureGenetic Complementation TestGlucoseGlycohemoglobin AGlycosylated hemoglobin AGoalsHIVHIV AntibodiesHIV CareHIV anti-retroviralHIV disease transmissionHIV individualsHIV infected individualsHIV infected personsHIV infection spreadHIV infection transmissionHIV interventionHIV loadHIV medical careHIV patient careHIV peopleHIV plasma viral loadHIV positive individualsHIV positive peopleHIV related careHIV related patient careHIV spreadHIV testHIV therapeuticHIV therapyHIV transmissionHIV treatmentHIV viral burdenHIV viral loadHIV viral transmissionHIV-1 careHIV-1 interventionHIV-1 loadHIV-1 spreadHIV-1 testHIV-1 therapeuticHIV-1 therapyHIV-1 transmissionHIV-1 treatmentHIV-1 viral burdenHIV-1 viral loadHIV-1 virus transmissionHIV-2 testHIV-Associated AntibodiesHIV/AIDS transmissionHTLV-III AntibodiesHTLV-III-LAV AntibodiesHb A1Hb A1a+bHb A1cHbA1HbA1cHealthHealth Care ProvidersHealth PersonnelHealth systemHemoglobin A(1)HeterogeneityHourHuman Immunodeficiency Virus Type 1 transmissionHuman Immunodeficiency Virus therapyHuman Immunodeficiency Virus treatmentHuman Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III AntibodiesHuman immunodeficiency virus testIndividualInfrastructureLAV AntibodiesLAV-HTLV-IIILaboratoriesLateralLow-resource areaLow-resource communityLow-resource environmentLow-resource regionLow-resource settingLymphadenopathy-Associated AntibodiesLymphadenopathy-Associated VirusMath ModelsMeasuresMedicationModalityModelingMolecular InteractionMonitorPLWHPWHPatternPerformancePharmaceutical PreparationsPolymerase Chain ReactionPopulationPublic HealthROC AnalysesROC CurveRandomized, Controlled TrialsRecommendationResearchResearch SpecimenResource-constrained areaResource-constrained communityResource-constrained environmentResource-constrained regionResource-constrained settingResource-limited areaResource-limited communityResource-limited environmentResource-limited regionResource-limited settingResource-poor areaResource-poor communityResource-poor environmentResource-poor regionResource-poor settingRoleRunningSalesSensitivity and SpecificitySpecimenStandardizationSub-Saharan AfricaSubsaharan AfricaSurvey InstrumentSurveysTestingTimeTrans TestTreatment EffectivenessUnited StatesViralViral BurdenViral LoadViral Load resultVirus-HIVVisitantibody assayantibody based testantibody based therapiesantibody biosynthesisantibody testantibody titeringantibody treatmentantibody-based therapeuticsantibody-based treatmentcare costscare of HIV-1care providersclinical applicabilityclinical applicationcohortcomplementationcomplementation analysiscomplementation approachcostcost effectivenessdata modelingdiagnostic algorithmdrug adherencedrug compliancedrug/agentemerging epidemicepidemic containmentepidemic controlepidemic mitigationepidemic responsehealth assessmenthealth care personnelhealth care workerhealth providerhealth staffhealth workershealth workforcehealthcare employeeshealthcare staffhealthcare workforcehemoglobin A1chuman immunodeficiency virus carehuman immunodeficiency virus transmissionimmunoglobulin biosynthesisimprovedindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinstrumentmathematic modelmathematical modelmathematical modelingmedical care providersmedical personnelmedication adherencemedication compliancemodel of datamodel the datamodeling of the datanew epidemicnovelnovel epidemicpeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspoint of carepopulation basedprogramsprospectiverandomized control trialrapid assayrapid testrapid testsreceiver operating characteristic analysesreceiver operating characteristic curvesample collectionsocial rolespecimen collectionspread of human immunodeficiency virustest striptreat HIVtreat Human Immunodeficiency Virustreatment providerviral RNAviral detectionviral reboundviral testingvirus RNAvirus detectionvirus reboundvirus testing
Description preview
Polymerase chain reaction (PCR) testing for HIV viral load is a mainstay of HIV treatment monitoring, but has
limitations including high costs, long turn-around times, and limited information that only reflects viral load “in
the moment.” This study explores the hypothesis that low-cost rapid antibody tests can complement HIV PCR,
analogously to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click